When cells survive, we can protect against the effects of inflammation
Our anti-aging glycopeptide, AAGP®, works as a dual agent in a way that could protect and recover skin from ultraviolet (UV) radiation or harsh chemicals or assist in the treatment of atopic dermatitis and burn injuries. For the millions of individuals who suffer from skin conditions worldwide, AAGP® could have a role to play in helping prevent sun damage, inflammation, scarring, or signs of aging and more.
The impact of AAGP®
Chronic skin conditions can be both physically and mentally painful. In the United States, more than 85 million people are affected by skin conditions each year, according to the American Academy of Dermatology. AAGP® can recover skin cells after the damage is done, as demonstrated in a laboratory setting. As a result, this molecule has the potential to make treatments for skin conditions more accessible and affordable.
We’re researching two major ways that AAGP® can help: inflammation protection as well as UV-radiation and burn recovery.
The most common dermatological issue is inflammation. This can cause chronic conditions like eczema or rosacea. Occasional rashes can also occur from exposures to natural or chemical agents and sensitivities.
Your skin is your largest organ. When it becomes inflamed, visible reactions can happen. Figuring out what’s wrong and getting your skin back to normal is hard enough without answering questions from family and strangers about what’s wrong with your skin.
We’re in the preclinical research stage of discovering AAGP®’s ability to protect skin from inflammation and are working hard to advance AAGP® to clinical skin trials.
UV radiation and burn recovery
At ProtoKinetix, we calculate the market value of AAGP® in how well it can take care of patients. We want to help medical treatments become more successful in improving lives and helping cells survive. But we know that as an investor, you also want to know how our biotechnology can help you.
The 2025 market forecast for the dermatology industry is $183 billion. Investing in the future of dermatological medicine will help you and the millions of people around the world who are living with skin conditions live higher quality lives. The potential of our anti-aging glycopeptide is endless, and we’ve only seen the tip of the iceberg.
Invest with us
ProtoKinetix has patented an anti-aging glycopeptide with the power to change lives through cell survival. The potential is endless, and we’ve only seen the tip of the iceberg. Get invested.
We’re already making headlines with our groundbreaking research on the impact AAGP® could have in the field of dermatology.